The rapid mainstream adoption of GLP-1 weight-loss medications is beginning to send ripples through the global fashion and apparel industry — altering body sizes, shifting purchasing behaviour, and raising complex questions around inventory, returns and garment construction. What was once a medical conversation is now very much a retail and textile one.
Drugs such as Ozempic, Wegovy and Mounjaro have become closely associated with what commentators are calling the ‘Ozempic economy’ — a phenomenon in which significant shifts in consumer body weight are prompting people to replace clothing more frequently and reconsider how, where, and what they buy. The GLP-1 fashion impact is no longer speculative; it is measurable.
What the Research Is Telling Retailers
Research from PwC offers some of the clearest evidence yet of the GLP-1 drugs’ effect on apparel spending. Among US GLP-1 users surveyed, 73% reported a meaningful change in their clothing size. More strikingly, apparel spending among users was 9.9% higher after they had been taking the medications for six to eight months — a figure that points to a substantial and sustained shift in consumer behaviour.
The GLP-1 fashion impact is also registering strongly in the United Kingdom. PwC estimates that approximately three million British adults are currently using GLP-1 medications, with 40% of those surveyed indicating they were spending more on clothing as a direct result of their changing physique.
Physical Retail May See an Unlikely Revival
One of the more unexpected consequences of this trend could be a renewed preference for in-store shopping over online purchasing. A US survey of 500 GLP-1 users conducted by returns management specialist ReturnPro found that 69% of respondents had grown less confident about online sizing as their bodies continued to change — making the ability to try garments on in a physical store increasingly important to them.
The same survey found that 71% of GLP-1 users were buying more apparel as their size changed, while 58% reported increased apparel spending on premium or higher-priced clothing. Notably, more than half of those surveyed expected their clothing expenditure to rise further once their weight had stabilised, suggesting the demand uplift may be far from over.
Returns and Inventory — The Challenges Behind the Opportunity
The trend carries both opportunity and operational complexity for retailers. ReturnPro’s findings reveal that 65% of GLP-1 consumers surveyed were purchasing multiple sizes of the same garment with the intent to return those that did not fit — a behaviour that places additional strain on already stretched returns infrastructure. Some 43% said their frequency of apparel returns had increased, and almost half had already returned clothing that had become too large before it was ever worn.
Beyond returns, the evolving size landscape is complicating inventory planning. PwC cautions that rapidly shifting demand patterns could make historical size distribution data a far less reliable tool for retailers when deciding how many garments to stock in each size. For a sector that depends on predictive accuracy, that is a meaningful challenge.
The resale market, meanwhile, could stand to benefit. As consumers simultaneously clear out wardrobes that no longer fit and search for replacements in smaller sizes, the secondary clothing market is well positioned to absorb both sides of that exchange.
What This Means for Textile and Apparel Manufacturers
Beyond Smaller Sizes — The Emphasis on Garment Comfort and Fit
For manufacturers, the implications of the GLP-1 fashion impact extend well beyond producing more garments in smaller sizes. Bodies in transition — uncertain of their eventual size and shape — are likely to place growing importance on clothing fit, stretch, garment comfort and adaptable construction. The consumer is becoming more attuned to how a garment feels, not just how it looks.
An Industry Shift That Is Difficult to Ignore
The full scale of the GLP-1 drugs’ effect on fashion is still unfolding, and weight-loss medications represent just one among many forces influencing apparel markets. But with millions of consumers potentially moving through several clothing sizes — and altering their spending, shopping channels and return habits along the way — the consequences for sizing standards, clothing fit, returns management, resale volumes and inventory planning are becoming increasingly difficult for the industry to set aside.
The Ozempic fashion conversation, it seems, has only just begun.
